Llwytho...
The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma
Doxorubicin (DOX) is one of the widely used chemotherapeutic drugs for the treatment of human osteosarcoma (OS). However, acquisition of DOX resistance is common in patients with OS, leading to local and distant failure. In this study, we demonstrate that survivin expression is significantly upregul...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Int J Clin Exp Med |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
e-Century Publishing Corporation
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4694298/ https://ncbi.nlm.nih.gov/pubmed/26770398 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|